Paper Review Records
All Paper Review Records
12 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
314
days
Illuminating the future: energy-based focal therapies for prostate cancer
Authors
Anirban Goutam Mukherjee; Abilash Valsala GopalakrishnanShow moreShow less
Affiliations
1. Department of Biotechnology, School of Sciences and Humanities, SR University, Warangal, India; 2. Department of Biomedical Sciences, School of Bio-Sciences and Technology, Vellore Institute of Technology, Vellore, IndiaShow moreShow less
46
days
Robotic-assisted versus open radical nephrectomy with inferior vena cava thrombectomy for renal cell carcinoma: a systematic review and meta-analysis of perioperative outcomes and oncological endpoints
Authors
Diego Villalobos-Almanza; Alfredo Salazar-Monroy; Daniel Olvera‐PosadaShow moreShow less
Affiliations
1. Hospital Zambrano HellionShow moreShow less
66
days
MiR-590 suppresses the progression of non-small cell lung cancer by regulating YAP1 and Wnt/β-catenin signaling
Authors
X. Hao; A. SuShow moreShow less
Affiliations
1. Department of Internal Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China; 2. General Department, Bejing Chaoyang District Sanhuan Cancer Hospital, Beijing, ChinaShow moreShow less
70
days
Human umbilical cord mesenchymal stem cell-derived exosomes carrying hsa-miRNA-128-3p suppress pancreatic ductal cell carcinoma by inhibiting Galectin-3
Authors
X. Xie; J. Ji; X. Chen; W. Xu; H. Chen; S. Zhu; J. Wu; Y. Wu; Y. Sun; W. Sai; Z. Liu; M. Xiao; B. BaoShow moreShow less
Affiliations
1. Department of Gastroenterology, Affiliated Hospital and Medical School of Nantong University, Nantong, China; 2. Office of Infection Management, Affiliated Hospital of Nantong University, Nantong, China; 3. Department of Gastroenterology, Second People’s Hospital of Nantong, Nantong, China; 4. Medical School of Nantong University Oral Medicine, Nantong, China; 5. Blood Center of Jiangsu Province, Nanjing, China; 6. Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, ChinaShow moreShow less
46
days
Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines
Authors
P. García-Alfonso; M. Saiz-Rodríguez; R. Mondéjar; J. Salazar; D. Páez; A. M. Borobia; M. J. Safont; I. García-García; R. Colomer; X. García-González; M. J. Herrero; L. A. López-Fernández; F. Abad-SantosShow moreShow less
Affiliations
1. Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Sociedad Española de Oncología Médica (SEOM), Madrid, Spain; 2. Research Unit, Fundación Burgos por la Investigación de la Salud (FBIS), Hospital Universitario de Burgos, Sociedad Española de Farmacogenética y Farmacogenómica (SEFF), Burgos, Spain; 3. Medical Oncology Service, Hospital Universitario de la Princesa, Sociedad Española de Oncología Médica (SEOM), Madrid, Spain; 4. Research Institute of Hospital de la Santa Creu I Sant Pau, Sociedad Española de Farmacogenética y Farmacogenómica (SEFF), Barcelona, Spain; 5. Medical Oncology Department, Hospital de la Santa Creu I Sant Pau, Sociedad Española de Oncología Médica (SEOM), Barcelona, España; 6. Clinical Pharmacology Service, Hospital Universitario La Paz, Sociedad Española de Farmacogenética y Farmacogenómica (SEFF), Madrid, Spain; 7. Medical Oncology Service, Consorcio Hospital General Universitario de Valencia, Universidad de Valencia, CIBERONC, Sociedad Española de Oncología Médica (SEOM), Valencia, Spain; 8. Medical Oncology Service, Hospital Universitario de La Princesa y Cátedra de Medicina Personalizada de Precisión de la Universidad Autónoma de Madrid (UAM), Sociedad Española de Oncología Médica (SEOM), Madrid, Spain; 9. Hospital Pharmacy Service, Hospital General Universitario Gregorio Marañón, Sociedad Española de Farmacogenética y Farmacogenómica (SEFF), Madrid, Spain; 10. Pharmacogenetics Platform, IIS La Fe-Hospital La Fe and Pharmacology Department, Universidad de Valencia, Sociedad Española de Farmacogenética y Farmacogenómica (SEFF), Valencia, Spain; 11. Clinical Pharmacology Service, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, Sociedad Española de Farmacogenética y Farmacogenómica (SEFF), Madrid, SpainShow moreShow less
56
days
Tumor immune microenvironment is influenced by frameshift mutations and tumor mutational burden in gastric cancer
Authors
H. Kim; Y. J. Heo; Y. A. Cho; S. Y. Kang; S. Ahn; K. -M. KimShow moreShow less
Affiliations
1. Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; 2. The Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; 3. Department of Pathology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Republic of KoreaShow moreShow less
FAQ
How long does Clinical & Translational Oncology take to review a manuscript?
As of 2026-11-19, CrushSCI has 12 complete review records for Clinical & Translational Oncology. The fastest paper went from submission to acceptance in 16 days (Future care for long-term cancer survivors: towards a new model, received 2021-07-26, accepted 2021-08-11); the slowest took 314 days. The average is 78.2 days and the median is 55 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
